Key Takeaways
- American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk rose Tuesday after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China.
- Ozempic, another drug with the same active ingredient, was approved for sale in China in 2021 and has helped boost Novo Nordisk’s revenue in the region.
- The weight-loss drugs have boosted Novo Nordisk’s earnings around the world, while U.S.-based competitor Eli Lilly has seen similar success with its drugs Mounjaro and Zepbound.
American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) rose Tuesday on the New York Stock Exchange (NYSE) after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China.
The treatment for overweight and obese patients was approved “recently” by China’s National Medical Products Administration, according to a translation of a Chinese release from Novo Nordisk released Tuesday morning.
Novo Nordisk’s Ozempic and Wegovy have exploded in popularity over the last several years, boosting the company’s earnings and stock price to make it the most valuable company in Europe, while its U.S. competitor Eli Lilly (LLY) has seen similar growth thanks to its weight-loss drugs Mounjaro and Zepbound.
Wegovy To Join Ozempic in Treating Obesity, Diabetes in China
Novo Nordisk said it held 76.6% of the GLP-1 market for treating diabetes in the mainland China, Hong Kong, and Taiwan region as of last November, and said its 6.21 billion Danish kroner ($890.7 million) in 2023 sales represented year-over-year growth of nearly 80% at constant exchange rates.
The Danish drugmaker did not release information Tuesday about how much Wegovy will cost in China, or how much of the drug it plans to sell in the country as it continues to deal with demand outpacing supply in much of the world for Ozempic and Wegovy.
The company said in March that it expected approval in China sometime this year, with many patients expected to pay out of pocket after the drug launches, according to Reuters. Novo Nordisk’s patent for Wegovy in China expires in 2026, the report said.
The announcement comes a day after Novo Nordisk said it plans to spend just over $4 billion expanding its U.S. manufacturing with a new facility in North Carolina as part of a broader $6.8 billion effort to boost capacity this year. The company has also completed a number of acquisitions over the last year to increase its production.
ADRs of Novo Nordisk were up nearly 3% to $146.49 as of 10 a.m. ET Tuesday, and have risen over 40% so far this year.